Literature DB >> 19190104

Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia.

Rubina A Heptulla1, Luisa M Rodriguez, Kimberly J Mason, Morey W Haymond.   

Abstract

CONTEXT: The purpose of this study was to examine the effect of continuous sc replacement of amylin and insulin for a 24-h period on glucose homeostasis in adolescents with type 1diabetes.
METHODS: Thirteen adolescents with type 1 diabetes on insulin pump therapy participated in a randomized, controlled, crossover design study comparing continuous sc insulin monotherapy (part A) vs. continuous sc insulin and pramlintide infusion (part B). In part A, basal and bolus insulin infusion was per prescribed home regimen. In part B, the basal insulin infusion was the same as part A, but prandial insulin boluses were reduced by 20%. Basal and prandial bolus pramlintide were administered simultaneously via another pump. All boluses were given as a dual wave.
RESULTS: The study regimen resulted in a 26% reduction in postprandial hyperglycemia as compared to insulin monotherapy (area under the curve, 600 min, 2610 +/- 539 vs. 692 +/- 861 mg/liter . min) (P < 0.008). Glucagon concentrations were suppressed postprandially (P < 0.003) but not in the postabsorptive state, whereas plasma insulin concentrations were unchanged.
CONCLUSIONS: Simultaneous continuous sc pramlintide and insulin infusion has the potential of improving glucose concentrations by way of physiological replacement.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190104      PMCID: PMC2684475          DOI: 10.1210/jc.2008-2580

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Authors:  Christian Weyer; Alan Gottlieb; Dennis D Kim; Karen Lutz; Sherwyn Schwartz; Maria Gutierrez; Yan Wang; James A Ruggles; Orville G Kolterman; David G Maggs
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

2.  Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.

Authors:  M Samsom; L A Szarka; M Camilleri; A Vella; A R Zinsmeister; R A Rizza
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-06       Impact factor: 4.052

3.  Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.

Authors:  L Orskov; B Nyholm; K Yde Hove; C H Gravholt; N Møller; O Schmitz
Journal:  Diabet Med       Date:  1999-10       Impact factor: 4.359

4.  The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.

Authors:  Rubina A Heptulla; Luisa M Rodriguez; Lisa Bomgaars; Morey W Haymond
Journal:  Diabetes       Date:  2005-04       Impact factor: 9.461

Review 5.  Modulation of gastric emptying as a therapeutic approach to glycaemic control.

Authors:  C Moyses; A Young; O Kolterman
Journal:  Diabet Med       Date:  1996-09       Impact factor: 4.359

6.  The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.

Authors:  B Nyholm; L Orskov; K Y Hove; C H Gravholt; N Møller; K G Alberti; C Moyses; O Kolterman; O Schmitz
Journal:  Metabolism       Date:  1999-07       Impact factor: 8.694

7.  Dose-response for glucagonostatic effect of amylin in rats.

Authors:  B R Gedulin; T J Rink; A A Young
Journal:  Metabolism       Date:  1997-01       Impact factor: 8.694

8.  The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.

Authors:  Luisa M Rodriguez; Kimberly J Mason; Morey W Haymond; Rubina A Heptulla
Journal:  Pediatr Res       Date:  2007-12       Impact factor: 3.756

9.  Decreased epinephrine responses to hypoglycemia during sleep.

Authors:  T W Jones; P Porter; R S Sherwin; E A Davis; P O'Leary; F Frazer; G Byrne; S Stick; W V Tamborlane
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

10.  Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy: impact of glycemic index and prandial bolus type.

Authors:  Michele A O'Connell; Heather R Gilbertson; Susan M Donath; Fergus J Cameron
Journal:  Diabetes Care       Date:  2008-05-28       Impact factor: 19.112

View more
  6 in total

Review 1.  A review of the treatment of type 2 diabetes in children.

Authors:  Erin St Onge; Shannon A Miller; Carol Motycka; Adrienne DeBerry
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jan-Feb

Review 2.  Adjunct therapy for type 1 diabetes mellitus.

Authors:  Harold E Lebovitz
Journal:  Nat Rev Endocrinol       Date:  2010-04-20       Impact factor: 43.330

3.  In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.

Authors:  Francesco Micheletto; Chiara Dalla Man; Orville Kolterman; Elaine Chiquette; Kathrin Herrmann; Jörg Schirra; Boris Kovatchev; Claudio Cobelli
Journal:  Diabetes Technol Ther       Date:  2013-07-18       Impact factor: 6.118

4.  Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.

Authors:  Venkat Sasidhar Renukuntla; Neesha Ramchandani; Jeniece Trast; Martin Cantwell; Rubina A Heptulla
Journal:  J Diabetes Sci Technol       Date:  2014-07-16

5.  Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.

Authors:  Jeniece Trast Ilkowitz; Ranjitha Katikaneni; Martin Cantwell; Neesha Ramchandani; Rubina A Heptulla
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

6.  Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function.

Authors:  Ernest Adeghate; Huba Kalász
Journal:  Open Med Chem J       Date:  2011-09-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.